HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Attila Nagy Selected Research

RC 121

6/2006Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
5/2005Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
2/2002Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
2/2002Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Attila Nagy Research Topics

Disease

32Neoplasms (Cancer)
01/2022 - 02/2002
10Carcinoma (Carcinomatosis)
12/2005 - 02/2002
8Prostatic Neoplasms (Prostate Cancer)
02/2006 - 02/2002
7Endometrial Neoplasms (Endometrial Cancer)
11/2005 - 09/2002
5Body Weight (Weight, Body)
02/2011 - 02/2002
5Ovarian Neoplasms (Ovarian Cancer)
03/2005 - 09/2002
4Neoplasm Metastasis (Metastasis)
01/2022 - 04/2003
4Ischemic Stroke
01/2021 - 01/2017
4Breast Neoplasms (Breast Cancer)
12/2005 - 09/2003
3Colonic Neoplasms (Colon Cancer)
01/2022 - 02/2002
3Chronic Obstructive Pulmonary Disease (COPD)
07/2019 - 08/2018
3Melanoma (Melanoma, Malignant)
06/2006 - 09/2004
3Pancreatitis
12/2004 - 03/2002
2Inflammation (Inflammations)
02/2022 - 03/2015
2Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 02/2002
2Metabolic Syndrome (Dysmetabolic Syndrome X)
06/2021 - 05/2018
2Stroke (Strokes)
11/2019 - 01/2013
2Intracranial Hemorrhages (Intracranial Hemorrhage)
11/2019 - 01/2017
2Insulin Resistance
05/2019 - 10/2017
2Hypertension (High Blood Pressure)
05/2018 - 02/2011
2Necrosis
12/2016 - 03/2002
2Renal Cell Carcinoma (Grawitz Tumor)
11/2005 - 08/2005
2Pancreatic Neoplasms (Pancreatic Cancer)
10/2005 - 09/2004
2Lymphoma (Lymphomas)
09/2005 - 05/2005
2Glioblastoma (Glioblastoma Multiforme)
07/2005 - 09/2004
2Jaundice (Icterus)
12/2004 - 07/2004
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
09/2004 - 04/2003
2Brain Neoplasms (Brain Tumor)
09/2004 - 04/2003
2Lung Neoplasms (Lung Cancer)
09/2004 - 04/2003
1Respiratory Tract Diseases (Respiratory Tract Disease)
09/2022
1Critical Illness (Critically Ill)
02/2022
1Paramyxoviridae Infections (Parainfluenza)
01/2022
1COVID-19
01/2022
1Type 2 Diabetes Mellitus (MODY)
02/2021
1Diabetes Mellitus
02/2021
1Cardiovascular Diseases (Cardiovascular Disease)
01/2021
1Cough
12/2020
1Atrial Fibrillation
09/2020
1Airway Obstruction (Choking)
08/2019
1Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
05/2019
1Obesity
04/2019
1Cystic Fibrosis (Mucoviscidosis)
01/2019
1Lung Diseases (Lung Disease)
01/2019

Drug/Important Bio-Agent (IBA)

18AN 204 (AN 201)IBA
06/2006 - 02/2002
16Gonadotropin-Releasing Hormone (GnRH)FDA Link
02/2006 - 02/2002
13Doxorubicin (Adriamycin)FDA LinkGeneric
02/2006 - 02/2002
11Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
06/2006 - 02/2002
11Messenger RNA (mRNA)IBA
12/2005 - 02/2002
10AN 238IBA
06/2006 - 02/2002
10LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
02/2006 - 02/2002
10BombesinIBA
01/2006 - 04/2003
9AN 207IBA
02/2006 - 02/2002
9AN 215IBA
01/2006 - 10/2003
9lysine(6)-doxorubicin LHRHIBA
11/2005 - 09/2002
8Proteins (Proteins, Gene)FDA Link
01/2019 - 10/2002
7AndrogensIBA
05/2019 - 02/2002
6Somatostatin Receptors (Somatostatin Receptor)IBA
06/2006 - 02/2002
5Gastrin-Releasing PeptideIBA
01/2006 - 09/2004
4Tissue Plasminogen Activator (Alteplase)FDA Link
01/2021 - 01/2017
4RC 121IBA
06/2006 - 02/2002
4RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
10/2005 - 02/2002
3Biomarkers (Surrogate Marker)IBA
02/2022 - 04/2012
3LipidsIBA
04/2019 - 10/2017
2Pharmaceutical PreparationsIBA
09/2022 - 08/2018
2Factor XIII (Coagulation Factor XIII)IBA
01/2021 - 01/2018
2Glucose (Dextrose)FDA LinkGeneric
05/2018 - 10/2017
2Membrane Transport Proteins (Biological Pump)IBA
11/2005 - 09/2005
2Peptide Receptors (Peptide Receptor)IBA
11/2005 - 09/2004
2Antineoplastic Agents (Antineoplastics)IBA
11/2005 - 10/2005
2LigandsIBA
10/2005 - 05/2003
2Triptorelin Pamoate (Trelstar)FDA Link
08/2005 - 10/2003
2BilirubinIBA
12/2004 - 07/2004
2Peptides (Polypeptides)IBA
09/2004 - 04/2003
2ErbB Receptors (EGF Receptor)IBA
10/2003 - 10/2002
2pentetreotide (OctreoScan)FDA Link
05/2003 - 04/2003
1Blood Coagulation Factors (Coagulation Factor)IBA
01/2022
1Dipeptidyl-Peptidase IV InhibitorsIBA
02/2021
1Blood Glucose (Blood Sugar)IBA
02/2021
1CholesterolIBA
01/2021
1AerosolsIBA
12/2020
1DabigatranFDA Link
09/2020
1Vitamin KFDA Link
09/2020
1Plasminogen Activator Inhibitor 1IBA
11/2019
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
05/2019
1Cyproterone AcetateIBA
05/2019
1Ethinyl Estradiol (Estinyl)FDA LinkGeneric
05/2019
1Metformin (Glucophage)FDA LinkGeneric
05/2019

Therapy/Procedure

23Drug Therapy (Chemotherapy)
06/2006 - 02/2002
22Therapeutics
11/2019 - 02/2002
3Aftercare (After-Treatment)
05/2019 - 09/2002
3Injections
09/2003 - 02/2002
2Conservative Treatment
12/2016 - 02/2011
1Length of Stay
02/2022
1Adjuvant Chemotherapy
01/2022
1Nursing Care
01/2022
1Home Nursing (Nursing, Home)
01/2022
1Oral Hygiene (Dental Hygiene)
06/2021
1Catheter Ablation
09/2020
1Tracheotomy
08/2019
1Nebulizers and Vaporizers (Inhaler)
07/2019